TEVA (tevapharm.com) צמיחת רווח למניה השנה

Teva Pharmaceutical Industries (TEVA) maintains its leadership due to a massive volume of generics and strict FDA oversight. Year-over-year EPS changes demonstrate a recovery phase following prolonged litigation and restructuring. However, disruptions in Asian logistics create risks of raw material shortages. Meanwhile, the -30.00 indicator reflects the status of current business yield relative to previous periods.
פילוחי מדדים מקיפים ואנליטיקה עבור tevapharm.com (TEVA)

To assess the fundamental stability of Teva Pharmaceutical Industries (TEVA), it is critical to analyze cost management efficiency through the outsourcing of production and logistics. The current year-over-year EPS trend, captured by the value -30.00, measures the percentage change in net profit per share over twelve months, allowing investors to determine the real growth rate of returns and avoid the risks of capital freeze.